Spyre Therapeutics, Inc. (SYRE)
(Delayed Data from NSDQ)
$16.36 USD
+0.12 (0.74%)
Updated Sep 29, 2025 03:59 PM ET
After-Market: $16.40 +0.04 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SYRE 16.36 +0.12(0.74%)
Will SYRE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SYRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SYRE
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%
SYRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?
Other News for SYRE
Crossed Above 20 Day Moving Average appears for SYRE after 4.04% move
Fell Below 20 Day Moving Average appears for SYRE after 8.18% move
Deutsche Bank Initiates Coverage on Spyre Therapeutics (SYRE) with 'Buy' Rating | SYRE Stock News
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Spyre Therapeutics initiated with a Buy at Deutsche Bank